BEAM

Key Statistics

Latest News

Beam Therapeutics Clarifies Growth Path With PKU Program And New Financing

Simply Wall St. 3 days ago

BEAM's Q4 Loss Narrower Than Expected, Revenues Rise Y/Y

Zacks 4 days ago

RBC Capital Adjusts Beam Therapeutics Price Target to $26 From $22, Maintains Sector Perform - Speculative Risk Rating

MT Newswires 4 days ago

Beam Therapeutics Inc. Q4 2025 Earnings Call Summary

Moby 4 days ago

Sector Update: Health Care Stocks Softer Late Afternoon

MT Newswires 4 days ago

Peers in Health Care

Community Sentiment

Sign in to vote

0 votes

Discussion (0)

About Beam Therapeutics Inc.

Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. Its programs in hematology and genetic disease portfolio include Ristoglogene autogetemcel, a patient-specific, autologous hematopoietic stem cell (HSC) therapy for the treatment of sickle cell disease; BEAM-302, a liver-targeting lipid nanoparticle (LNP) for the treatment of severe alpha-1 antitrypsin deficiency; BEAM-304, a liver-targeting LNP for the treatment of phenylketonuria; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease type 1a. The company also develops the ESCAPE platform, which combines antibody-based conditioning with multiplex gene edited HSCs. In addition, it develops BEAM-103, an anti-CD117 monoclonal antibody that enables ESCAPE. The company has research collaboration agreement with Pfizer Inc., focusing on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Verve Therapeutics, Inc., for cardiovascular disease treatments; and Orbital Therapeutics to design RNA for the prevention, treatment, or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.